Parkman Healthcare Partners LLC Takes $3.12 Million Position in Artivion, Inc. $AORT

Parkman Healthcare Partners LLC bought a new position in shares of Artivion, Inc. (NYSE:AORT) during the second quarter, HoldingsChannel reports. The institutional investor bought 138,940 shares of the company’s stock, valued at approximately $3,122,000.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Artivion during the 2nd quarter worth $149,965,000. Vanguard Group Inc. boosted its position in Artivion by 4.7% in the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after buying an additional 141,030 shares during the last quarter. Morgan Stanley grew its stake in shares of Artivion by 0.8% during the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after acquiring an additional 18,248 shares in the last quarter. State Street Corp grew its stake in shares of Artivion by 2.9% during the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after acquiring an additional 44,641 shares in the last quarter. Finally, Fred Alger Management LLC increased its position in shares of Artivion by 4.2% during the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after acquiring an additional 55,322 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on AORT. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price target on shares of Artivion in a research note on Monday, July 20th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research note on Monday, June 1st. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Citizens Jmp reduced their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Artivion has an average rating of “Moderate Buy” and an average target price of $44.83.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 977 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares in the company, valued at approximately $5,245,521.82. The trade was a 0.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 114,978 shares of company stock valued at $2,965,155 in the last quarter. Insiders own 6.30% of the company’s stock.

Artivion Stock Performance

Shares of AORT stock opened at $27.07 on Tuesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. Artivion, Inc. has a one year low of $19.16 and a one year high of $48.25. The company’s 50-day simple moving average is $25.20 and its 200-day simple moving average is $29.96. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -386.66 and a beta of 1.24.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Equities analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.